Mini Review - Journal of Pharmaceutical Toxicology (2022) Volume 5, Issue 5

Involvement of CUL4A in Regulation of Multidrug Resistance to P-gp Substrate Drugs in Breast Cancer Cells

M Harpaz*

Department of Human Anatomy and Key Laboratory of Experimental Teratology, Ministry of Education, Shandong University School of Medicine, 44 Wenhua Xi Road, Jinan 250012, Shandong, China

*Corresponding Author:
M Harpaz Department of Human Anatomy and Key Laboratory of Experimental Teratology, Ministry of Education, Shandong University School of Medicine, 44 Wenhua Xi Road, Jinan 250012, Shandong, ChinaE-mail:

Received: 01-Aug-2022, Manuscript No: jpt-22-72478; Editor assigned: 04-Aug-2022, PreQC No: jpt-22- 72478 (PQ); Reviewed: 18-Aug-2022, QC No: jpt-22-72478; Revised: 22- Aug-2022, Manuscript No. jpt-22- 72478 (R); Published: 30-Aug-2022, DOI: 10.37532/jpt.2022.5(5).62-65


Adr cells independently. Using rear recap polymerase chain responses and western spots, we set up that overexpression of CUL4A in MCF7 and MDA- MB- 468 cells up- regulated MDR1/ Pgp expression on both the recap and protein situations, which conferred multidrug resistance to P-gpsubstrate medicines, as determined by 3,5-dimethylthiazol-2-yl) platitude( MTT) assays. On the contrary hand, silencing CUL4A in MCF7/ Adr and MDA- MB- 468/ Adr cells led to the other effect. also, ERK1/ 2 in CUL4A- overexpressing cells was largely actuated and after treatment with PD98059, an ERK1/ 2-specific asset, CUL4A- convinced expression of MDR1/ Pgp was dropped significantly. Incipiently, immunohistochemistry in melanoma napkins showed that P-gpexpression had a positive correlation with the expression of CUL4A and ERK1/2. Therefore, these results inferred that CUL4A and ERK1/ 2 shared inmate- drug resistances in melanoma through regulation of MDR1/ Pgp expression.


Multidrug resistant • P- glycoprotein • CUL4A • melanoma


Preface CUL4A, a recently set up oncogene, is amplified in bone cancers. It encodes a core element of a culling- grounded E3 ubiquitin ligase complex. This complex regulates numerous critical processes like cell cycle progression, DNA replication, DNA form and chromatin redoing by targeting a spread of proteins for ubiquitination and declination. In bone cancers, over-expression of CUL4A explosively correlates with poor prognostic [1, 2]. Recent exploration showed that CUL4A features a relationship with MDR in prostate cancer too, but the connection between CUL4A and MDR and related mechanisms in bone cancer are still unclear. The mitogen- actuated protein kinase (MAPK) pathway is a beautiful target for remedial intervention in cancer due to its integral part in the regulation of cancer cell proliferation, invasiveness, and survival. Extracellular signal- regulated kinase (ERK) may be a member of the MAPK family [3]. The exertion of ERK1/ 2 has been intertwined within the regulation of embryonic morphogenesis, cell proliferation, excrescence metamorphosis, and apoptosis. It’s been lately set up that CUL4A accommodate ERK1/ 2 expressions by conforming H3K4 methylation position on its protagonist region in PC3 cell line [4]. Further, we note that we did not identify a set of expected signals that we hoped to find (e.g., expected adverse drug events) or avoid (e.g., confounded signals). Rather, since others have identified GPS as a potentially valuable tool for signal detection, our goal was to investigate the feasibility of implementing GPS and Tree Scan in a real-world large-scale data mining application using longitudinal electronic health data without limiting the analysis to pre- specified relationships. We reviewed the product label, medical literature, and consulted clinical experts (co-authors and others) to informally assess whether identified signals were known or reasonably expected due to confounding. In our view there is no clear and well defined list of all known adverse drug events [5, 6]. Most drug labels have extensive adverse event list, but there is no conclusive evidence that all these “adverse events” are caused by the drug [7]. For black box warnings there is usually strong evidence, but most known adverse events do not generate a black box warning. Developing a comprehensive list of all possible adverse events was beyond the scope of the paper and inconsistent with our primary aim to assess implementation in a real world setting [8, 9].


Electronic healthcare databases hold promise for Pharmacovigilance because they address common shortcomings inherent to spontaneous reporting systems, offer large sample sizes and the potential to study subgroups, and include longitudinal medical information for a defined population. This is the first study to apply the GPS to population- based observational data in a multi-site environment for assessment of non-pre specified outcomes [10]. Prior studies have implemented GPS in similar environments but have focused on pre-specified drug-event pairs we identified 71 signals across four drug products. Of the 48 GPS signals identified, 23 (48%) signaled at the highest threshold. We did not formally evaluate each signal for clinical plausibility or prior knowledge of association, or prioritize them for refinement [11, 12]. All GPS signals were either known associations or could be reasonably attributed to confounding. We counted as unique every signal at each level of the hierarchical tree, an approach that overestimates the number of signals that would require refinement under a real-world implementation [13]. For example, we counted signals for Diseases of the Nervous System and Sense Organs (06), Eye Disorders (06.07), Cataracts (06.07.01), and Glaucoma (06.07.03) as four distinct signals, although the higher-level signals (06 and 06.07) were almost entirely made up of the two lower-level signals and would not require four distinct signal refinement activities [14].


It has been reported that CUL4A is essential for ubiquitination of several well- defined excrescence suppressors, including p21, p27, DDB2, and p53. This study suggests that CUL4A activates ERK1/ 2 pathways. Overexpression of CUL4A dramatically increased ERK1/ 2 protein situations while knockdown of CUL4A remarkably dropped ERK1/ 2 exertion. Unexpectedly our results also suggested that the regulation of ERK1/ 2 by CUL4A is thru recap regulation rather than ubiquitination. Some studies have showed that CUL4A regulates histone methylation. We further showed that CUL4A up regulates ERK1/ 2 expression through enrichment of trim ethylated H3K4 on ERK1 and ERK2 promoters. Importantly, CUL4A- convinced nasty phenotype are frequently incompletely reversed by ERK1/ 2 asset PD98059, which further suggests that CUL4A exerts the oncogenic effect in melanoma through up regulation of ERK1/ 2. We also set up that the ERK1/ 2 assets PD98059 led to significant cure-dependent inhibition of P-gpexpression in the CUL4A overexpression cells. Next we covered CUL4A- intermediated perceptivity to P-gpsubstrate medicines after ERK1/ 2 asset PD98059 treatment in MCF7- CUL4A cells. Dispensable to say, CUL4A-intermediated dropped perceptivity to P-gp substrate medicines were downgraded by ERK1/ 2 assets PD98059. Thus, ERK1/2 activation could be one possible medium for the CUL4A convinced P-gp expression situations in MCF7- CUL4A cells.


Bone cancer, one among the most frequent malice in women worldwide, may be a complex and naturally miscellaneous complaint, which develops through the buildup of a wide diapason of genomic rarities ultimately leading to oncogenic parcels similar as immortalization, stromal irruption, and metastasis. MDR has been considered a significant problem in the treatment of numerous cancers including bone cancer. MDR is intermediated by complex mechanisms and one among the major mechanisms is the expression of the MDR1 decoded P-gp, which has been verified to be liable for the resistance to several unconnected cancer chemotherapeutic medicines. Overexpression of the efflux pump MDR1/ P-gp leads to the dropped accumulation and toxin of numerous anticancer medicines, like doxorubicin, paclitaxel, and etoposide, performing in chemotherapeutic failure. Although chemotherapy has bettered the survival rate of melanoma cases for decades, relatively 80 cases that entered chemo- medicines will ultimately develop MDR after ages of treatment, performing in treatment failure. Thus, new strategies to benefit MDR bone cancer cases are urgently needed. Although several impediments modulators of MDR1/ P-gpare developed, cytotoxic goods and adverse pharmacokinetics have banned their use. Presently available impediments also warrant the energy to reverse the MDR phenotype fully at clinically attainable attention. Fortunately, molecular target remedy has shown pledge in preclinical studies, supported multitudinous signaling pathways that play places in the regulation of MDR1/ P-gpexpression. Compared with Tree Scan, there are both strengths and weaknesses to GPS, and it may be ideal to employ both methods simultaneously, using the combined results to better strengthen, refute, and understand signals. Strength of the GPS method is the Bayesian probability intervals; shrinkage of the point estimates towards the population average of O/E is a possible strength, although care must be taken to insure “shrinkage” towards values over unity does not introduce signals. We suggest future implementations carefully assess the GPS parameter sets to understand the distribution of O/E in the underlying population. A major strength of the Tree Scan is the formal adjustment for multiple testing and the ability to analyze different levels of disease granularity in a single combined analysis.


In summary, our work confirms that CUL4A regulates the expression of MDR1 via an ERK1/ 2 dependent signaling pathway in melanoma cells, which is according to their differences in cellular multidrug resistance in vitro To assess their multidrug chemo sensitivity, transfected cells and their corresponding control cells were plated in 96- well plates at a viscosity of 5 × 103 cells/ well and further incubated for twenty- four h. The medium was also removed and replaced with fresh medium containing paclitaxel (Sigma), vincristine (Sigma), Adriamycin, bleomycin, and camptothecin independently, with varying attention for an fresh 48h. also, cells were stained with 20 L sterile MTT color( 3-(,5- dimethylthiazol-2-yl) platitude, 5 mg/ mL; Sigma) at 37 °C for 4 h followed by removing the medium and mixing with 150 L of dimethyl sulfoxide ( DMSO) completely for 10 min. Spectrometric absorbance at 490 nm was measured with a micro plate anthology. Each group contained three wells and was repeated 3 times. The IC50 value decided by the cure of medicine that caused 50 cell viability. We note that using observational data for signal detection requires complex and often subjective analytic specifications, often unstated, that can directly affect the interpretation of the findings. Our implementation applied common epidemiologic approaches such as allowing individuals to contribute exposed and unexposed person time, and most importantly, involved identification of non-specified incident outcomes. The pilot was conducted using a fully distributed approach that did not require sharing of person-level protected health data but allowed identical definitions and analyses to be performed at each data partner.



Conflict of Interest

No conflict of interest


  1. Denton LK, Creeley CE, Stavola B, et al. An analysis of online pregnancy message boards: Mother-to-mother advice on medication use. Women Birth. 33, e48–e58 (2020).
  2. Upattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: A cross-sectional, multinational web-based study. BMJ Open. 4, e004365 (2014).
  3. Gerbier E, Graber SM, Rauch M, et al. Use of drugs to treat symptoms and acute conditions during pregnancy in outpatient care in Switzerland between 2014 and 2018: Analysis of Swiss healthcare claims data. Swiss Med Wkly. 151, w30048 (2021).
  4. Indexed at, Google Scholar, Crossref

  5. Ceulemans M, Van Calsteren K, Allegaert K, et al. Health products’ and substance use among pregnant women visiting a tertiary hospital in Belgium: A cross-sectional study. Drug Saf. 28, 1231-1238(2019).
  6. Indexed at, Google Scholar, Crossref

  7. Gerbier E, Favre G, Tauqeer F, et al. Self-reported medication use among pregnant and postpartum women during the third wave of the COVID-19 pandemic: A European multinational cross-sectional study. Int J Environ Res Public Health. 19, 5335(2022).
  8. Indexed at, Google Scholar, Crossref

  9. Schenkel L, SimõesWüst AP, Hösli I, et al. Drugs in Pregnancy and Lactation—Medications Used in Swiss Obstetrics. Geburtshilfe Neonato.  222, 152-165(2018).
  10. Indexed at, Google Scholar, Crossref

  11. Holst L, Wright D, Haavik S, et al. Safety and efficacy of herbal remedies in obstetrics-review and clinical implications. Midwifery. 27, 80-86 (2011).
  12. Indexed at, Google Scholar, Crossref

  13. Harris-Sagaribay L, Chambers CD, Perrotta K, et al. A model partnership for communication and dissemination of scientific recommendations for pregnant women during the emergency response to the Zika virus outbreak: MotherToBaby and the Centers for Disease Control and Prevention. Birth Defects Res. 112, 1545-1550 (2020).
  14. Indexed at, Google Scholar, Crossref

  15. Richardson JL, Stephens S, Yates LM, et al. Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services. Reprod Toxicol. 67, 26-34 (2017).
  16. Indexed at, Google Scholar, Crossref

  17. Panchaud A, Rousson V, Vial T et al. Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. Br J Clin. Pharmaco.  84, 568-578 (2018).
  18. Indexed at, Google Scholar, Crossref

  19. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy—15 years experience of ENTIS. Reprod Toxicol. 20, 331-343 (2005).
  20. Indexed at, Google Scholar, Crossref

  21. Winterfeld U, Merlob P, Baud D et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology. 86, 2251-2257 (2016).
  22. Indexed at, Google Scholar, Crossref

  23. Vorstenbosch S, Te Winkel B, van Gelder M, et al. Aim and Design of pREGnant, the Dutch Pregnancy Drug Register. Drug Saf. 42, 1-12 (2019).
  24. Indexed at, Google Scholar, Crossref

  25. Chambers C, Johnson DL, Kiernan E. Approach to evaluating pregnancy safety of anti-rheumatic medications in the OTIS Mother to Baby pregnancy studies: What have we learned? Rheumatology. 57, v34-v39 (2018).
  26. Indexed at, Google Scholar, Crossref